Launch and Commercial Maximization
CAPABILITIES
Case Study 1: Launching a Gene Therapy for Rare Genetic Disorder
Situation:
A pharmaceutical company was preparing to launch a first-in-class gene therapy for a rare genetic disorder. Despite its groundbreaking potential, the product faced hurdles related to high pricing, complex administration, and payer skepticism.
Our Role:
We conducted an in-depth market access and payer strategy assessment, focusing on establishing the therapy’s value. Our team developed tailored messaging for payers, KOLs, and advocacy groups, crafted materials to educate both healthcare providers and caregivers, and provided a detailed roadmap for navigating reimbursement processes.
Impact:
The launch achieved swift market adoption, with 75% of target payers agreeing to coverage within the first six months. The gene therapy exceeded initial revenue projections by 25% as a result of our strategic approach, driving both access and awareness in a niche market.
Case Study 2: Indication Expansion for an ADC in Oncology
Situation:
A pharmaceutical client sought to expand the label of their approved antibody-drug conjugate (ADC) to a new oncology indication, aiming to differentiate against other treatment options and maximize the therapy’s clinical impact.
Our Role:
We led a strategic indication expansion plan that included competitive analysis, engagement with oncologists, and messaging focused on the ADC’s unique mechanism of action and clinical advantages. Our team supported a proactive medical education campaign to highlight the product’s efficacy and safety profile for the new indication.
Impact:
The ADC achieved rapid adoption in the new indication, capturing a 30% market share within the first year. Our tailored approach positioned the therapy as a preferred option among oncologists, helping drive new patient starts and maximizing the commercial potential of the ADC.